SCHEMBL16616669

SCHEMBL16616669

CCCc1nc(OCc2ccccc2)c(C(=O)O)cc1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 2/20 0.48
BAK1 Q16611 1/20 0.48
PPARG P37231 1/20 0.45
ADORA3 P0DMS8 1/20 0.43
ADORA1 P30542 1/20 0.43
KDM4E B2RXH2 1/20 0.43
SLC16A3 O15427 1/20 0.43
CNR1 P21554 2/20 0.42
PTGES O14684 1/20 0.42
ALOX5 P09917 1/20 0.42
FOLH1 Q04609 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
LTB4R Q15722 1/20 0.40
LTB4R2 Q9NPC1 1/20 0.40
DHODH Q02127 1/20 0.40
TSHR P16473 1/20 0.40
MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28848476 0.92 CNR1 (0.49) MCL1BAK1PPARGADORA3ADORA1
SCHEMBL16616128 0.89 MCL1 (0.50) MCL1BAK1PPARGSLC16A3CNR1
SCHEMBL16616554 0.86 CNR1 (0.51) MCL1BAK1PPARGADORA3ADORA1
SCHEMBL28166409 0.81 CNR1 (0.53) MCL1BAK1PPARGSLC16A3CNR1
SCHEMBL16616758 0.81 MCL1 (0.55) MCL1BAK1PPARGSLC16A3FOLH1
SCHEMBL16616609 0.75 CNR1 (0.55) MCL1BAK1PPARGCNR1MEN1
SCHEMBL9337371 0.75 MCL1 (0.50) MCL1BAK1PPARGPTGESALOX5
SCHEMBL12076414 0.75 CTSV (0.51) MCL1BAK1PPARGKDM4ESLC16A3
SCHEMBL16616016 0.74 MCL1 (0.46) MCL1BAK1PPARGKDM4ESLC16A3
SCHEMBL16624313 0.73 CNR1 (0.53) MCL1BAK1PPARGKDM4ECNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3055309-B1 ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) TAKEDA PHARMACEUTICALS CO (JP) 2018-06-13 EP disclosed
US-9751878-B2 Tetrahydronaphthyridine somatostatin receptor 5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-09-05 US disclosed
US-20160237087-A1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-08-18 US disclosed
EP-3055309-A1 ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) Takeda Pharmaceutical Company Limited (JP) 2016-08-17 EP disclosed
US-9353108-B2 Tetrahydronaphthyridine somatostatin receptor 5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-05-31 US disclosed
WO-2015052910-A1 ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-16 WO disclosed
US-20150099777-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099777-A1 HETEROCYCLIC COMPOUND SSTR5, SSTR4, SSTR2 MCL1 4200/4885BAK1 1379/4885PPARG 459/4885
US-20160237087-A1 HETEROCYCLIC COMPOUNDS SSTR5, SSTR4, SSTR2 MCL1 4034/4885BAK1 1465/4885PPARG 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.